Alligator Bioscience to attend ASCO 2025 Annual Meeting
Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023
Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...
Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022
Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens ...
Alligator Bioscience to Present at 10th Annual Immuno-Oncology Summit, October 12 -14, 2022
Lund, Sweden, October 10, 2022 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announced that Mattias Levin, PhD, Sr Team Ma ...